Myriad offers an array of genetic tests, prognostic tests, and personalized medicine tests to healthcare providers to help them assess a patient’s increased cancer risk, disease aggressiveness, optimize efficacy of chemotherapy and identify patients most suitable for therapy.

Companion diagnostics

MyChoice® CDx Plus product signature

MyChoice® CDx Plus is the most comprehensive tumor test that determines HRD status in patients with ovarian cancer, fallopian tube and primary peritoneal cancer. This CE marked test helps to identify ovarian cancer patients with a Homologous Recombination Deficiency who might be considered for treatment with PARPi therapy.

Learn more

MyChoice® CDx Plus is the most comprehensive tumor test that determines HRD status in patients with ovarian cancer, fallopian tube and primary peritoneal cancer. This CE marked test helps to identify ovarian cancer patients with a Homologous Recombination Deficiency who might be considered for treatment with PARPi therapy.

Learn more

MyChoice® CDx product signature

MyChoice® CDx is the first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status.

Learn more

MyChoice® CDx is the first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status.

Learn more

BRACAnalysis CDx product signature

BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).

Learn more

BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).

Learn more

Hereditary cancer testing

MyRisk™ product signature

Myriad MyRisk Hereditary Cancer is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.
Learn more

Myriad MyRisk Hereditary Cancer is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.
Learn more

Prognostic testing

Prolaris<sup>®</sup> product signature

Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.

Learn more

Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.

Learn more

EndoPredict product signature

EndoPredict® is the only test that answers the following three important clinical questions…

  • Can chemotherapy be avoided? (individual risk at 10 years)
  • What is the absolute benefit from chemotherapy? (individual chemotherapy benefit)
  • Can endocrine therapy be stopped after 5 years? (individual risk up to 15 years)

… to optimize treatment for breast cancer patients.

Learn more

EndoPredict® is the only test that answers the following three important clinical questions…

  • Can chemotherapy be avoided? (individual risk at 10 years)
  • What is the absolute benefit from chemotherapy? (individual chemotherapy benefit)
  • Can endocrine therapy be stopped after 5 years? (individual risk up to 15 years)

… to optimize treatment for breast cancer patients.

Learn more

No results found for

Please try changing the search criteria, or reset filters